Clinical trial readout dates for Glaukos Corporation, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is April 2027.
| Phase 2 GLK-221 Ophthalmic Solution Keratoconus · NCT07400952 | April 2027 Recruiting |
| Phase 2 Gen 2 Travoprost Intracameral Implant Glaucoma · NCT07075718 | March 2028 Recruiting |
| Phase 3 Gen 2 Travoprost Intracameral Implant Glaucoma · NCT07495852 | June 2028 Recruiting |
Glaukos Corporation reported $337M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-28). It reported net income of $2M for that quarter.
| 8-K Reg FD Disclosure — often a data announcement | 2026-11-06 |
| 8-K Reg FD Disclosure — often a data announcement | 2026-10-28 |